1. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
- Author
-
Dana Shalmon, Efrat Bar-Ilan, Alon Peled, Shamir Geller, Jonathan Bar, Naama Schwartz, Eli Sprecher, and Mor Pavlovsky
- Subjects
autoimmune blistering disease ,bullous pemphigoid ,bullous drug reaction ,drug reaction ,dipeptidyl peptidase 4 inhibitor ,gliptin ,Dermatology ,RL1-803 - Abstract
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008–2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid. Based on a multivariable analysis adjusted for age and other covariates, Alzheimer’s disease and other dementias were significantly more prevalent in patients with bullous pemphigoid (p = 0.0013). Concomitant use of either thiazide or loop diuretics and gliptin therapy was associated with drug-associated bullous pemphigoid (p
- Published
- 2024
- Full Text
- View/download PDF